Screener
Ginkgo Bioworks DNA Stock-Based Comp
Stock-Based Comp at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Ginkgo Bioworks in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Ginkgo Bioworks’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:09 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-054298
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Net loss from continuing operations | (133,380) | (136,504) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 25,114 | 30,071 |
| Stock-based compensation | 23,448 | 36,189 |
| (Gain) loss on investments | (773) | 3,958 |
| Loss on equity method investment | 4,673 | — |
| Change in fair value of notes receivable | 6,759 | 5,285 |
| Change in fair value of contingent consideration | — | (4,232) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Ginkgo Bioworks's stock-based comp?
- Ginkgo Bioworks (DNA) reported stock-based comp of $7.6M in Q2 2026.
- How has Ginkgo Bioworks's stock-based comp changed year-over-year?
- Ginkgo Bioworks's stock-based comp decreased by 59.6% year-over-year, from $18.8M to $7.6M.
- What is the long-term trend for Ginkgo Bioworks's stock-based comp?
- Over 4 years (2021 to 2025), Ginkgo Bioworks's stock-based comp has grown at a -52.5% compound annual growth rate (CAGR), from $1.61B to $81.55M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Ginkgo Bioworks's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude